Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

13.42 -0.06 (-0.45%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,461,701
Open	13.50
Bid (Size)	13.00 (2,100)
Ask (Size)	13.55 (100)
Prev. Close	13.48
Today's Range	13.24 - 13.67
52wk Range	11.76 - 34.29
Shares Outstanding	9,587,155
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know ↗

April 21, 2026

Viridian Therapeutics is a clinical-stage biotech awaiting an FDA decision on its lead thyroid eye disease therapy.

Via The Motley Fool

Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment

April 13, 2026

THOUSAND OAKS, Calif. – In a move that significantly strengthens its hold on the thyroid eye disease (TED) market, Amgen (NASDAQ: AMGN) recently announced pivotal Phase 3 topline results for its...

Via MarketMinute

Performance

YTD	-56.3%	-56.3%
1 Month	-28.8%	-28.8%
3 Month	-59.6%	-59.6%
6 Month	-42.0%	-42.0%
1 Year	-1.5%	-1.5%

More News

Amgen Reclaims the Lead in Thyroid Eye Disease with Superior Subcutaneous TEPEZZA Data

April 09, 2026

Via MarketMinute

Which stocks are moving on Monday? ↗

April 06, 2026

Via Chartmill

Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones

April 02, 2026

Via MarketMinute

Which stocks are experiencing notable movement on Monday? ↗

March 30, 2026

Via Chartmill

Here are the top movers in Monday's session. ↗

March 30, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Monday's session. ↗

March 30, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

March 30, 2026

Via Chartmill

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

March 30, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗

March 21, 2026

Via The Motley Fool

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Via The Motley Fool

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗

March 18, 2026

Via The Motley Fool

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗

March 18, 2026

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

Via The Motley Fool

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

Via The Motley Fool

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

February 26, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

February 23, 2026

Via The Motley Fool

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 08, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Prepares for Transformational 2026

January 06, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗

January 02, 2026

Via The Motley Fool

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

December 22, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Inc (NASDAQ:VRDN) Shows High-Growth Momentum and Strong Technical Setup ↗

December 18, 2025

Via Chartmill

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 07, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Viridian Therapeutics, Inc. - Common Stock publicly traded?

Yes, Viridian Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Viridian Therapeutics, Inc. - Common Stock trade on?

Viridian Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Viridian Therapeutics, Inc. - Common Stock?

The ticker symbol for Viridian Therapeutics, Inc. - Common Stock is VRDN on the Nasdaq Stock Market

What is the current price of Viridian Therapeutics, Inc. - Common Stock?

The current price of Viridian Therapeutics, Inc. - Common Stock is 13.42

When was Viridian Therapeutics, Inc. - Common Stock last traded?

The last trade of Viridian Therapeutics, Inc. - Common Stock was at 05/01/26 04:00 PM ET

What is the market capitalization of Viridian Therapeutics, Inc. - Common Stock?

The market capitalization of Viridian Therapeutics, Inc. - Common Stock is 128.66M

How many shares of Viridian Therapeutics, Inc. - Common Stock are outstanding?

Viridian Therapeutics, Inc. - Common Stock has 129M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.